Clinico-immunological disorders in patients with ischemic heart disease and metabolic syndrome: Correction with nebivolol

Terapevticheskii Arkhiv

Volumn 80, Issue 12, 2008, Pages 44-52

  Teplyakov, A T ^a   Bolotskaya, L A ^a   Vdovina, T V ^a   Stepacheva, T A ^a   Kuznetsova, A V ^a  

^a NONE

Author keywords

Immune disorders; Ischemic heart disease; Metabolic syndrome; Nebivolol

Indexed keywords

BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; ETHANOLAMINE DERIVATIVE; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; LIPID; NEBIVOLOL;

ANGINA PECTORIS; ARTICLE; BLOOD; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; IMMUNOLOGY; INSULIN RESISTANCE; LEUKOCYTE; LEUKOCYTE COUNT; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; T LYMPHOCYTE; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; ANTIGENS, CD; BENZOPYRANS; CYTOKINES; DIABETES MELLITUS, TYPE 2; ETHANOLAMINES; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; IMMUNOGLOBULINS; INSULIN RESISTANCE; LEUKOCYTE COUNT; LEUKOCYTES; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 60749110437     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Kaplan N. M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 1989; 149: 1514-1520.
3. Haffner S. M., Feranini E., Hazuda H. P., Stern M. P. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992; 20: 38-45.
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Hone J., Accili D., Al-Gazali L. I. et al. Homozygosity for a new mutation (ILe-Met) in the insulin receptor gene in five sibs with familial insulin resistance. J. Med. Genet. 1994; 31: 715-716.
10. Taylor S. L. Lilly lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473-1490.
11. 3 - adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N. Engl. J. Med. 1995; 333: 348-351.
12. Chiu K. C., McCarthy J. E. The insertion allele at the angiotensin I-converting enzyme gene locus is associated with insulin resistance. Metabolism 1997; 46: 395-399.
13. Cole S. A., Aston C. E., Hamma R. E. et al. Association of a Pvull RFLP at the lipoprotein lipase locus with fasting insulin levels in Hispanic men. Genet. Epidemiol. 1993; 10: 177-188.
14. Femander-Real S. M., Gutierresc., Ricart W. et al. The TNF-α gene Neo I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997; 46: 1468-1472.
15. Russian source
16. Russian source
17. Russian source
18. Russian source
19. Russian source
20. Accili D., Cama A., Barbetti F. et al. Insulin resistance due to mutation of the insulin receptor gene: an overview. J. Endocrinol. Invest. 1992; 15: 857-864.
21. Steiner G. The dyslipoproteinemias of diabetes. Atherosclerosis 1994; 110: 27-33.
22. Sakamoto T., Woodcocke-Mitchell J., Maratsuka K. et al. TNF-α and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am. J. Physiol. 1999; 276: C1391-C1397.
23. UK Prospective Diabetes Study Group (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
24. Gao Y., Nagao T., Bond R. A. et al. Nebivolol induces en-dothelium-dependent relaxation of canine coronary arteries. J. Cardiovasc. Pharmacol. 1991; 7: 964-969.
25. Russian source
26. Russian source
27. Russian source
28. Ohtsuka T., Hamada M., Hiasa G. et al. Effects of beta-blocers on circulating levels of inflammatory and anti-inflaminatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001; 37: 412-417.
29. Russian source
30. Russian source
31. Russian source
32. Russian source
33. Russian source
34. Russian source
35. Russian source
36. G. K. in: Hansson G. K., Libby P., eds. Immune functions of the vessel wall. New York; 1996. 143-157.
37. Russian source